Company reported ZILRETTA ( triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter Demand for ZILRETTA from healthcare providers increased month-over-month throughout the second quarter with total demand in line with the first
BURLINGTON, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference . The
BURLINGTON, Mass. , May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be
BURLINGTON, Mass. , May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an
BURLINGTON, Mass. , May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
Company reported ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020 Flexion implementing broad cost savings initiatives; guiding to total operating expenses in the range of $167 million to $177 million for 2020 Phase 2
FX201 preclinical in vivo data in a rodent model of OA showed slowing of disease progression 12 weeks post-surgery, persistence of the vector genome in the joint for at least 92 days with absence of systemic distribution, and a favorable safety profile Productivity, purification yields, and product
An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA® Analysis of patient mobility indicated patients treated with ZILRETTA walked more steps per day in concert with pain reduction Survey of 1,000 patients with
BURLINGTON, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020 . Flexion’s management will host a conference call at
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of
